APA-Zitierstil (7. Ausg.)

Landgren, O., Prior, T. J., Masterson, T., Heuck, C., Bueno, O. F., Dash, A. B., . . . Devlin, S. M. (2024). EVIDENCE meta-analysis: Evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma. Blood, 144(4), . https://doi.org/10.1182/blood.2024024371

Chicago-Zitierstil (17. Ausg.)

Landgren, Ola, et al. "EVIDENCE Meta-analysis: Evaluating Minimal Residual Disease as an Intermediate Clinical End Point for Multiple Myeloma." Blood 144, no. 4 (2024). https://doi.org/10.1182/blood.2024024371.

MLA-Zitierstil (9. Ausg.)

Landgren, Ola, et al. "EVIDENCE Meta-analysis: Evaluating Minimal Residual Disease as an Intermediate Clinical End Point for Multiple Myeloma." Blood, vol. 144, no. 4, 2024, https://doi.org/10.1182/blood.2024024371.